Company Overview and News
July marks the ninth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $640.87.
SOJA GIS XOM SKT LTC OPRF SEP BPL MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI ETP ORI WPC SPG ADM
Good morning and welcome to the LTC Properties Second Quarter 2018 Analyst and Investor Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]
LTC Properties (LTC - Free Report) came out with quarterly funds from operations (FFO) of $0.75 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.79 per share a year ago. These figures are adjusted for non-recurring items.
ACTG LTC FANG
ltc_Current folio_10Q Table of Contents
This is the fourth month I have officially tracked dividend income (in an article) for John's Traditional and Roth IRA Accounts. His dividend income totaled $1,186.94.
PK POR SCG CAT XOM HTA RF LTC OPRF TD WMT KMI MSCA SCU OMI WELL KMR TD CVB ORCL BBT VTR DUKH GD NYSE TNTTF MAIN O PACW DUK KMB MSCA.CL PEP CLDT OXY KMRFZ
This is the third month I have officially tracked dividend income (in an article) for John's Traditional and Roth IRA Accounts. His combined dividend income totaled $908.43.
LMT POR SCG HTA LTC RF OPRF TD KMI MSCA AAPL SCU KMR TD CVB BBT SHBI DUKH GD NYSE TNTTF MAIN O PACW DUK MSCA.CL CLDT OXY KMRFZ
June marks the eighth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $676.96.
SOJA GIS XOM IDCC SKT LTC OPRF BPL SEP COP MIC CINF AAPL CAH EMR BBT SO TLP WLK O MSB OZRK CMI ETP HP ORI SPG WPC ADM
Some of you have asked me last week why STAG Industrial (STAG) was not listed in my top 10 “sleep well at night” list. As you may recall, I penned an article titled, 10 Great REITs To Own For The Next 10 Years,” which included the following best-in-class picks:
TM HTA LTC OPRF GM STAG KIM F O TYT TOYOF PLD 7203 SPG FCAU
Here we are with another installment of my "stock considerations" for the upcoming month. With the first week of trading upon us in July, it is time, once again, to lay out a plan for my potential stock pick(s) for the month. As many of you already know, I make sure to purchase at least one stock every single month, no matter where we are in a business or macroeconomic cycle. The goal of every long-term dividend growth investor is to remain consistent with their buys and try not to attempt to time the market and wait for the "best" possible time to invest.
SOJA HCN PM GIS HCP LTC SBRA WELL CAH ED JCI SBRAP VTR SO GE GEC D KMB PEP KHC GNE SBUX CLX
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET